Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Trial Network

Neither a doctor nor a teaching hospital

Research payments

$3,675,952

2,114 payments

Through program year 2025, Clinical Trial Network is reported as receiving $3,675,952 in research payments, across 2,114 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $264,351 46
2024 Research $596,123 677
2023 Research $1,525,415 741
2022 Research $747,019 494
2021 Research $37,526 99
2020 Research $165,889 19
2019 Research $339,630 38

Breakdown

Who paid Research payments · program years 2019–2025
  1. Alnylam Pharmaceuticals Inc. $1,837,907 1,944 payments
  2. Eisai Inc. $825,485 37 payments
  3. Novartis Pharmaceuticals Corporation $413,064 21 payments
  4. Adamas Pharmaceuticals, Inc. $153,119 44 payments
  5. AbbVie, Inc. $136,208 24 payments
  6. Cepheid $110,497 4 payments
  7. Genzyme Corporation $93,551 2 payments
  8. Biogen, Inc. $33,205 2 payments
  9. Genentech, Inc. $28,000 9 payments
  10. Ipsen Innovation $17,423 17 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) $827,567 1,202 payments
  2. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $825,485 37 payments
  3. Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) $766,449 476 payments
  4. A 5 Year Prospective Study of An Anti Amyloid Therapy Cad106 Or Cnp520 in Slowing and Or Postponing Cognitive Decline in Asymptomatic Apoe 4 Homozygotes at Risk for Developing Alzheimers Disease Dementia $200,467 2 payments
  5. A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) $196,486 137 payments
  6. A Randomized, Placebo Controlled, Investigator and Participant-blinded Study Investigating Safety, Tolerability, and Efficacy of RHH646 in Participants With Knee Osteoarthritis $137,792 4 payments
  7. A 3-Arm Multicenter Double-Blind Placebo-Controlled Randomized Study to Assess the Efficacy and Safety of Ads-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients With Walking Impairment $121,712 32 payments
  8. A Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Weeks Open-label to Assess Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants With Eosinophilic Esophagitis (EoE) $93,551 2 payments
  9. A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia $86,666 12 payments
  10. Xpert Xpress MVP $78,931 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record